{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:08:35Z","timestamp":1782310115555,"version":"3.54.5"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pathol.2025.11.002","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:20:09Z","timestamp":1765930809000},"page":"199-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Skeletal health in the precursor stages of multiple myeloma: fracture risk and bone phenotypes in monoclonal gammopathy of undetermined significance and smouldering myeloma"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-0928","authenticated-orcid":false,"given":"Melissa D.","family":"Cantley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Trainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma A-J.","family":"Cheney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Vandyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2025.11.002_bib1","series-title":"Cancer data in Australia","year":"2024"},{"key":"10.1016\/j.pathol.2025.11.002_bib2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pathol.2025.11.002_bib3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J Clinicians"},{"key":"10.1016\/j.pathol.2025.11.002_bib4","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pathol.2025.11.002_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pathol.2025.11.002_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41408-024-01026-6","article-title":"Large differences in age-specific survival in multiple myeloma in the nordic countries","volume":"14","author":"Hemminki","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.11.002_bib8","article-title":"Trends in 5-year cancer survival disparities by race and ethnicity in the US between 2002-2006 and 2015-2019","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.pathol.2025.11.002_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","article-title":"Pathogenesis of myeloma bone disease","volume":"109","author":"Roodman","year":"2010","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pathol.2025.11.002_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.11.002_bib11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00774-023-01403-4","article-title":"Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents","volume":"41","author":"Teramachi","year":"2023","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.pathol.2025.11.002_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2025.104268","article-title":"Updates on mechanisms of disease progression in precursor myeloma: monoclonal gammopathy of undermined significance and smoldering myeloma","volume":"54","author":"Saade","year":"2025","journal-title":"Presse Med"},{"key":"10.1016\/j.pathol.2025.11.002_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101242","article-title":"From MGUS to multiple myeloma: unraveling the unknown of precursor states","volume":"68","author":"Hevroni","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.pathol.2025.11.002_bib14","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/s41375-025-02654-y","article-title":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders","volume":"39","author":"Zanwar","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.11.002_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","article-title":"Smoldering multiple myeloma current treatment algorithms","volume":"12","author":"Rajkumar","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.11.002_bib16","series-title":"Clinical practice guideline: multiple myeloma","author":"Quach","year":"2022"},{"key":"10.1016\/j.pathol.2025.11.002_bib17","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.3390\/jcm13216461","article-title":"Trabecular bone score as a complementary tool for the assessment of bone mineral density in patients with asymptomatic monoclonal gammopathies","volume":"13","author":"Drakoulidou","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.pathol.2025.11.002_bib18","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1038\/s41375-025-02715-2","article-title":"High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease","volume":"39","author":"Toscani","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.11.002_bib19","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib20","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2025.11.002_bib21","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/bjh.19624","article-title":"The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)","volume":"205","author":"Ho","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pathol.2025.11.002_bib23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pathol.2025.11.002_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae266","article-title":"Controversies in smoldering multiple myeloma: finding the optimal approach for treatment initiation","volume":"30","author":"Ludwig","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.pathol.2025.11.002_bib25","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pathol.2025.11.002_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.11.002_bib27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.2024025415","article-title":"Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection","volume":"145","author":"Visram","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.11.002_bib28","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pathol.2025.11.002_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.11.002_bib30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","article-title":"New horizons in our understanding of precursor multiple myeloma and early interception","volume":"24","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pathol.2025.11.002_bib31","article-title":"Enhanced risk stratification of smoldering multiple myeloma with dynamic biomarkers: a multinational, multicenter study including 2,270 participants (PANGEA 2.0)","author":"Chabrun","year":"2025","journal-title":"Res Sq"},{"key":"10.1016\/j.pathol.2025.11.002_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: pathophysiology and management","volume":"2","author":"Silbermann","year":"2013","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.pathol.2025.11.002_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2025.100668","article-title":"Mechanistic insights into bone destruction in multiple myeloma: cellular and molecular perspectives","volume":"51","author":"Lungu","year":"2025","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.pathol.2025.11.002_bib34","article-title":"Myeloma bone disease: a constant problem in the changing landscape of myeloma management","author":"Swan","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.11.002_bib36","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2019.230011","article-title":"Fractures and survival in multiple myeloma: results from a population-based study","volume":"105","author":"Thorsteinsdottir","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2025.11.002_bib37","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.3390\/jcm11113088","article-title":"Newly diagnosed multiple myeloma patients with skeletal-related events and abnormal MRI pattern have poor survival outcomes: a prospective study on 370 patients","volume":"11","author":"Kanellias","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.pathol.2025.11.002_bib38","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2025.11.002_bib39","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.11.002_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2025.100680","article-title":"Treatment of myeloma bone disease: when, how often, and for how long?","volume":"52","author":"Gundesen","year":"2025","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.pathol.2025.11.002_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bjh.14815","article-title":"Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survival","volume":"179","author":"McIlroy","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.297.4.387","article-title":"Risk of subsequent fracture after low-trauma fracture in men and women","volume":"297","author":"Center","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.pathol.2025.11.002_bib43","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pathol.2025.11.002_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2018.100215","article-title":"Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: observations from real-world data","volume":"14","author":"Kim","year":"2019","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.pathol.2025.11.002_bib45","article-title":"Skeletal-related events in patients with multiple myeloma: a comprehensive retrospective cohort study","volume":"39","author":"Lee","year":"2024","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.pathol.2025.11.002_bib46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12885-020-6596-y","article-title":"Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review","volume":"20","author":"Mateos","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pathol.2025.11.002_bib47","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1158\/1078-0432.CCR-08-0666","article-title":"Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss","volume":"14","author":"Berenson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2025.11.002_bib48","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","article-title":"Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study","volume":"116","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.11.002_bib49","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00774-017-0817-8","article-title":"Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis","volume":"36","author":"Veronese","year":"2018","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.pathol.2025.11.002_bib50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.11.002_bib51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","article-title":"Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance","volume":"134","author":"Pepe","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.06269.x","article-title":"Fracture risk in patients with monoclonal gammopathy of undetermined significance","volume":"135","author":"Gregersen","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib53","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pathol.2025.11.002_bib54","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/bloodadvances.2017010454","article-title":"Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study","volume":"1","author":"Thorsteinsdottir","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2025.11.002_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.71","article-title":"Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance","volume":"5","author":"Piot","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.11.002_bib56","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ejh.13633","article-title":"Untangling fracture risk in monoclonal gammopathy of undetermined significance: a population-based cohort study","volume":"107","author":"Rognvaldsson","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-024-00980-5","article-title":"Mode of progression in smoldering multiple myeloma: a study of 406 patients","volume":"14","author":"Abdallah","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.11.002_bib58","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.3390\/jcm14072224","article-title":"Yearly assessment of bone disease in patients with asymptomatic multiple myeloma identifies early progression events and should be the standard clinical practice","volume":"14","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.pathol.2025.11.002_bib59","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1182\/bloodadvances.2025016083","article-title":"Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring","volume":"9","author":"Kastritis","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2025.11.002_bib60","article-title":"High rate of progression to symptomatic multiple myeloma in patients with smoldering myeloma and isolated osteoporotic vertebral fracture","volume":"21","author":"Chevalier","year":"2024","journal-title":"Bone Rep"},{"key":"10.1016\/j.pathol.2025.11.002_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115394","article-title":"Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance","volume":"137","author":"Sfeir","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.11.002_bib62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000162282","article-title":"Prevalence of monoclonal gammopathy of undetermined significance\/myeloma in patients with acute osteoporotic vertebral fractures","volume":"120","author":"Golombick","year":"2008","journal-title":"Acta Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/aam.aam_34_24","article-title":"Bone status in patients with monoclonal gammopathy of undetermined significance: a case-control study","volume":"24","author":"Taoubane","year":"2024","journal-title":"Ann Afr Med"},{"key":"10.1016\/j.pathol.2025.11.002_bib64","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/bmj.38376.401701.8F","article-title":"Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study","volume":"330","author":"Abrahamsen","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.pathol.2025.11.002_bib65","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00198-018-4787-z","article-title":"Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance","volume":"30","author":"Stein","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pathol.2025.11.002_bib66","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1182\/blood-2011-04-351437","article-title":"Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1alpha levels in patients with MGUS","volume":"118","author":"Ng","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.11.002_bib67","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00223-008-9145-2","article-title":"The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance","volume":"82","author":"Pepe","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.11.002_bib68","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood-2013-05-505776","article-title":"Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance","volume":"123","author":"Farr","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.11.002_bib69","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00774-020-01084-3","article-title":"Bone tissue quality in patients with monoclonal gammopathy of uncertain significance","volume":"38","author":"Orduna","year":"2020","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.pathol.2025.11.002_bib70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S2213-8587(18)30308-5","article-title":"Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study","volume":"7","author":"Samelson","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pathol.2025.11.002_bib71","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jbmr.3901","article-title":"HR-pQCT measures of bone microarchitecture predict fracture: systematic review and meta-analysis","volume":"35","author":"Mikolajewicz","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.11.002_bib72","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF02230356","article-title":"Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma","volume":"15","author":"Laroche","year":"1996","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.pathol.2025.11.002_bib73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02547214","article-title":"Quantitative histological data on disuse osteoporosis","volume":"17","author":"Minaire","year":"1974","journal-title":"Calcified Tissue Res"},{"key":"10.1016\/j.pathol.2025.11.002_bib74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0300-595X(73)80042-8","article-title":"Physiological senile involution and pathological rarefaction of bone. Quantitative and comparative histological data","volume":"2","author":"Meunier","year":"1973","journal-title":"Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.11.002_bib75","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1982.tb03936.x","article-title":"Quantitative histology of myeloma-induced bone changes","volume":"52","author":"Valentin-Opran","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib76","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pathol.2025.11.002_bib77","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/1097-0142(19911115)68:10<2241::AID-CNCR2820681024>3.0.CO;2-0","article-title":"Histologic, biochemical, and clinical parameters for monitoring multiple myeloma","volume":"68","author":"Bartl","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2025.11.002_bib78","first-page":"375","article-title":"Primary (essential) thrombocythemia versus polycythemia vera rubra. A histomorphometric analysis of bone marrow features in trephine biopsies","volume":"10","author":"Thiele","year":"1988","journal-title":"Anal Quant Cytol Histol"},{"key":"10.1016\/j.pathol.2025.11.002_bib79","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption","volume":"49","author":"Taube","year":"1992","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib80","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","article-title":"Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies","volume":"87","author":"Bataille","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.11.002_bib81","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.1995.tb05609.x","article-title":"Excessive bone resorption in human plasmacytomas: direct induction by tumour cells","volume":"90","author":"Bataille","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.1986.136","article-title":"Importance of quantitative histology of bone changes in monoclonal gammopathy","volume":"53","author":"Bataille","year":"1986","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pathol.2025.11.002_bib83","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.1990.tb07904.x","article-title":"Osteoblast stimulation in multiple myeloma lacking lytic bone lesions","volume":"76","author":"Bataille","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib84","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.13584","article-title":"High-dose therapy improves the bone remodelling compartment canopy coverage and bone formation in multiple myeloma","volume":"171","author":"Hinge","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib85","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.11.002_bib86","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Bonewald","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.11.002_bib87","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.abb.2014.05.003","article-title":"Osteoblast and osteocyte: games without frontiers","volume":"561","author":"Capulli","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.pathol.2025.11.002_bib88","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","article-title":"Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation","volume":"26","author":"Giuliani","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.11.002_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117236","article-title":"3D osteocyte lacunar morphometry of human bone biopsies with high resolution microCT: from monoclonal gammopathy to newly diagnosed multiple myeloma","volume":"189","author":"Moreno-Jimenez","year":"2024","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.11.002_bib90","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.11.002_bib91","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib92","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib93","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib94","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/leu.2010.173","article-title":"The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.11.002_bib95","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0609.1997.tb00932.x","article-title":"Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens","volume":"58","author":"Vejlgaard","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib96","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1080\/10428194.2017.1421757","article-title":"A role for bone turnover markers \u03b2-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma","volume":"59","author":"Vallet","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2025.11.002_bib97","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.pathol.2025.11.002_bib98","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/imj.13502","article-title":"Bisphosphonate guidelines for treatment and prevention of myeloma bone disease","volume":"47","author":"Lee","year":"2017","journal-title":"Intern Med J"},{"key":"10.1016\/j.pathol.2025.11.002_bib99","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/17474086.2025.2574716","article-title":"Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia","volume":"19","author":"Yong","year":"2026","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib100","series-title":"Clinical practice guideline: multiple myeloma","author":"Quach","year":"2017"},{"key":"10.1016\/j.pathol.2025.11.002_bib101","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pathol.2025.11.002_bib102","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the bone working group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2025.11.002_bib103","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2025.11.002_bib104","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect","volume":"118","author":"Martin","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib105","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","author":"D\u2019Arena","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2025.11.002_bib106","first-page":"243","article-title":"Multiple myeloma, macroglobulinemia and monoclonal gammopathies","author":"Durie","year":"1977","journal-title":"Recent Adv Haematol"},{"key":"10.1016\/j.pathol.2025.11.002_bib107","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood.V63.2.468.468","article-title":"Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment\u2014a prospective study of 160 patients","volume":"63","author":"Bataille","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.11.002_bib108","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0025-6196(12)60015-9","article-title":"\u201cBenign\u201d monoclonal gammopathy\u2014after 20 to 35 years of follow-up","volume":"68","author":"Kyle","year":"1993","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pathol.2025.11.002_bib109","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302525003484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302525003484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:42:09Z","timestamp":1777434129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302525003484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0031302525003484"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2025.11.002","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skeletal health in the precursor stages of multiple myeloma: fracture risk and bone phenotypes in monoclonal gammopathy of undetermined significance and smouldering myeloma","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2025.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia.","name":"copyright","label":"Copyright"}]}}